CD70 cDNA ORF Clone, Human, C-DDK (Flag®) tag General Information
Identical with the Gene Bank Ref. ID sequence.
Full length Clone DNA of Human CD70 molecule with Flag tag.
Enhanced CMV promoter
KpnI + XbaI (5.4kb + 0.63kb)
FLAG Tag Sequence: GATTACAAGGATGACGACGATAAG
T7( 5' TAATACGACTCACTATAGGG 3' )
BGH( 5' TAGAAGGCACAGTCGAGG 3' )
The plasmid is confirmed by full-length sequencing.
Antibiotic in E.coli
Antibiotic in Mammalian cell
Stable or Transient mammalian expression
Storage & Shipping
Each tube contains lyophilized plasmid.
The lyophilized plasmid can be stored at ambient temperature for three months.
**Sino Biological guarantees 100% sequence accuracy of all synthetic DNA constructs we deliver, but we do not guarantee protein expression in your experimental system. Protein expression is influenced by many factors that may vary between experiments or laboratories.**
CD70 cDNA ORF Clone, Human, C-DDK (Flag®) tag Alternative Names
CD27L cDNA ORF Clone, Human;CD27LG cDNA ORF Clone, Human;TNFSF7 cDNA ORF Clone, Human
CD70 Background Information
CD7, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD7 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD7 expression is required to prevent lethal immunodeficiency. By selective transcription, CD7 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD7 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD7 expression in multiple carcinoma types. The restricted expression pattern of CD7 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD7 as a cancer target have lead to the identification of potential antibody-based clinical candidates.Immune CheckpointImmune Checkpoint ProteinsImmune Checkpoint Targets Co-stimulatory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy
Adam PJ, et al. (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer. 95(3): 298-306.Keller AM, et al. (2007) Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proc Natl Acad Sci U S A. 104(14): 5989-94.Grewal IS. (2008) CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets. 12(3): 341-51.Boursalian TE, et al. (2009) Targeting CD70 for human therapeutic use. Adv Exp Med Biol. 647: 108-19.